Article
TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection
2022-12-09
Abstract excerpt
The COVID-19 pandemic remains a global health threat and novel antiviral strategies are urgently needed. SARS-CoV-2 employs the cellular serine protease TMPRSS2 for entry into lung cells and TMPRSS2 inhibitors are being developed for COVID-19 therapy. However, the SARS-CoV-2 Omicron variant, which currently dominates the pandemic, prefers the endo/lysosomal cysteine protease cathepsin L over TMPRSS2 for cell entry...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 56350f58-89bf-52c1-a1c1-cca57cfd97a4
- DOI
- 10.1101/2022.12.09.519765
